UK bootmaker Dr Martens has today stuck to its fiscal 2027 outlook, citing encouraging wholesale demand in its largest market, the US.
The company said that trading has been in line with expectations since the start of its financial year in April.
Dr Martens said Japan and South Korea were performing well and the European markets were also in line with expectations despite a challenging consumer backdrop.
In May, Dr Martens reported a revenue decline from the Europe, Middle East and Africa region as the economic fallout from the Iran war weighed on consumer spending.
The company is expected to report adjusted pretax profit of £68m for fiscal 2027, according to a company-compiled consensus.
